Celeste® Photo-Neuromodulation

About PhotoPharmics

PhotoPharmics is pioneering a novel, non-invasive phototherapy platform for neurodegenerative diseases, with an initial focus on Parkinson's disease. Its lead device, Celeste®, has shown promising improvements in motor and non-motor symptoms in a Phase 2 trial and is now being evaluated in a fully enrolled, FDA-aligned Phase 3 pivotal trial. The company is positioning its at-home therapy as a potential breakthrough adjunctive treatment that could become a new standard of care, with future ambitions to expand the platform to Alzheimer's and other neurodegenerative conditions.

Therapeutic Areas